Knight Therapeutics Inc. is a specialty pharmaceutical company that acquires, in-licenses, out-licenses, develops, manufactures, markets, and distributes prescription pharmaceutical products. The company operates in Canada, Latin America, and select international markets, excluding the United States. Its portfolio includes branded generic products, with recent regulatory approvals and launches in Brazil for NIKTIMVO and TAVALISSE. Knight Therapeutics holds an exclusive distribution agreement with Kyowa Kirin International for Poteligeo (Mogamulizumab). The company was incorporated in 2013.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Drug Manufacturers - Specialty & Generic Homepage investors.knighttx.com
Sector Healthcare IR page investors.knighttx.com/English/overview/default.aspx
Tags
specialty pharmaceuticals, branded generics, prescription drugs, pharmaceutical distribution, in-licensing, out-licensing, latin america, canada, NIKTIVO, TAVALISSE, Poteligeo, Mogamulizumab, Kyowa Kirin International
Press page investors.knighttx.com/English/news/default.aspx

Metrics

Valuation  
Market cap C$ 1.108B
Market cap (USD) $ 774.225M
P/E 74.48
PEG —
P/BV —
P/S 2.98
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -0.69%
ROI -0.64%
ROIC -0.64%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity 2.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 9.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue — 371.304M 328.199M 293.563M 243.478M 199.519M 47.461M 12.5M
Net profit -5.374M 4.332M -16.835M -29.892M 15.675M 42.067M 14.517M 24.079M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

10/29/2026

Download(opens in new window)

MONTREAL, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) pharmaceutical company, will release its third quarter 2026 financial results on Thursday, November 5, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date: Thursday, November 5, 2026

Time: 8:30 a.m. ET

Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677

Webcast**:** www.knighttx.com or Webcast

This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

Replay: An archived replay will be available for 30 days at www.knighttx.com .

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca .

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia Arvind Utchanah
President & Chief Executive Officer Chief Financial Officer
T: 514.484.4483 T. 514.484.4483
Email: [email protected] Email: [email protected]
Website: www.knighttx.com Website: www.knighttx.com

Primary Logo

Source: Knight Therapeutics

Multimedia Files:

View all news

Quick Links

IR Contact

Knight Therapeutics Inc.
100 Alexis Nihon Blvd,
Suite 600
Saint-Laurent, Quebec, H4M 2P2, Canada

[email protected]

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Knight Therapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Knight Therapeutics Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Quarterly Reports
Annual Reports
End of Day Stock Quote
Events & Presentations

Unsubscribe

Email Alert Sign Up Confirmation

REQUEST A MEETING WITH MANAGEMENT >

© Knight Therapeutics Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Knight Therapeutics Announces Launch of TAVALISSE® in Brazil Bull 3 Bear 0 Product/operations

10/06/2026

Download(opens in new window)

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1

“With today's launch, TAVALISSE® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI® and continues our track record of bringing innovative products to physicians and patients across Latin America," said Samira Sakhia, President and CEO of Knight Therapeutics.

Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to commercialize TAVALISSE® in Latin America. Since entering the agreement, Knight has made significant regulatory progress throughout the region and has submitted TAVALISSE® for regulatory approval in Brazil, Colombia, Mexico, Argentina and Paraguay and has obtained regulatory approval in Mexico in 2024, Brazil in May 2026, and Colombia in September 2026. The Company launched TAVALISSE® in Mexico in May 2026.

About TAVALISSE®

TAVALISSE® (fostamatinib disodium hexahydrate) is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently marketed in the United States under the brand name TAVALISSE (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.2

TAVALISSE® is a registered trademark of Rigel Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

About Chronic Immune Thrombocytopenia (ITP)

In patients with ITP, the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.3 People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.4

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com

or www.sedarplus.ca

.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca

. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

10/06/2026

Download(opens in new window)

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class mechanism that targets the underlying drivers of this debilitating condition, and we are proud to bring it to patients in Brazil. This approval reflects the strength of our partnership with Incyte and our shared commitment to ensuring that patients in Brazil have access to innovative therapies that can make a meaningful difference in their lives,” said Samira Sakhia, President and CEO of Knight Therapeutics.

In September 2021, Knight and Incyte (NASDAQ: INCY) had entered into an exclusive supply and distribution agreement for MINJUVI® (tafasitamab) and PEMAZYRE® (pemigatinib) in Latin America. In August 2025, Knight expanded its existing relationship with Incyte, to add exclusive rights to distribute ZYNYZ® (retifanlimab) and NIKTIMVO® (axatilimab) in Latin America. Under the terms of the amended agreement, Incyte is responsible for the development, manufacture and supply of such products to Knight, and Knight is responsible for seeking the necessary regulatory approvals and commercializing such products in Latin America.

About NIKTIMVO®

NIKTIMVO® (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).2

In September 2021, Syndax Pharmaceuticals, Inc. and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).

NIKTIMVO®, MINJUVI®, PEMAZYRE® and ZYNYZ® are trademarks of Incyte. All other trademarks are the property of their respective owners.

Prompts

Knight Therapeutics Inc. (ticker GUD), listed in Canada.

ETFs Holding Knight Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
DISV 0.05% 311,105 $ 2.629M Nov 12, 2026
DXIV 0.02% 6,100 $ 51.539K Nov 12, 2026
DFIS 0.02% 137,815 $ 1.164M Nov 12, 2026
AVDS 0.01% 4,903 $ 40.868K Nov 16, 2026
DFIC 0.01% 121,814 $ 1.029M Nov 12, 2026
DFAX 0.00% 62,345 $ 526.754K Nov 12, 2026
DFAI 0.00% 27,086 $ 228.85K Nov 12, 2026
AVDE 0.00% 77,384 $ 645.025K Nov 16, 2026